epiboxidine: an isoxazole analog of epibatidine; less toxic than epibatidine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5747670 |
SCHEMBL ID | 20741469 |
MeSH ID | M0277238 |
Synonym |
---|
188895-96-7 |
unii-xi646l2arj |
xi646l2arj , |
exo-2-(3-methyl-5-isoxazolyl)-7-azabicyclo(2.2.1)heptane |
(+-)-epiboxidine |
7-azabicyclo(2.2.1)heptane, 2-(3-methyl-5-isoxazolyl)-, exo- |
epiboxidine |
(+/-)-epiboxidine |
DTXSID20172258 |
rel-(1r,2s,4s)-2-(3-methyl-5-isoxazolyl)-7-azabicyclo(2.2.1)heptane |
7-azabicyclo(2.2.1)heptane, 2-(3-methyl-5-isoxazolyl)-, (1r,2s,4s)-rel- |
Q5382428 |
epiboxidine hcl |
5-[(1r,2s,4s)-7-azabicyclo[2.2.1]heptan-2-yl]-3-methyl-1,2-oxazole |
SCHEMBL20741469 |
CS-0173498 |
HY-138953 |
7-azabicyclo[2.2.1]heptane, 2-(3-methyl-5-isoxazolyl)-, (1r,2s,4s)-rel- |
rel-5-((1r,2s,4s)-7-azabicyclo[2.2.1]heptan-2-yl)-3-methylisoxazole |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 4 (57.14) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.00) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |